Dalbavancin: VERS completed enrollment of 60 hospitalized patients in an open-label Phase II trial of Dalbavancin. Patients will receive either once weekly or a

Versicor Inc. (VERS), Fremont, Calif. Product: Dalbavancin Business: Infectious diseases Therapeutic category: Bacterial infection Target: Bacterial cell walls Description: Second generation glycopept...